

GLAXOSMITHKLINE PLC

Form 6-K

April 17, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 17 April 2018

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No ☒

GlaxoSmithKline plc (the 'Company')

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Ms E Walmsley
b) Position/status Chief Executive Officer

- c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.

- | | Price(s) | Volume(s) |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | £14.296 | 3,639.339 |
| | £14.296 | 5,897.033 |
| | £14.296 | 7.046.678 |

- d) Aggregated information 16,583.050
Aggregated volume Price £14.296

- e) Date of the transaction 2018-04-12
f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr R G Connor
 - b) Position/status President, Global Manufacturing & Supply
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882								
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.								
c) Price(s) and volume(s)	<table border="0"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>£14.296</td> <td>2,125.159</td> </tr> <tr> <td>£14.296</td> <td>2,031.057</td> </tr> <tr> <td>£14.296</td> <td>2,793.963</td> </tr> </table>	Price(s)	Volume(s)	£14.296	2,125.159	£14.296	2,031.057	£14.296	2,793.963
Price(s)	Volume(s)								
£14.296	2,125.159								
£14.296	2,031.057								
£14.296	2,793.963								
d) Aggregated information									
Aggregated volume Price	6,950.178 £14.296								
e) Date of the transaction	2018-04-12								
f) Place of the transaction	London Stock Exchange (XLON)								

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr L Debruyne
 - b) Position/status President, Global Vaccines
 - c) Initial notification/ Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.
Price(s) Volume(s)
£14.296 534.931

- c) Price(s) and volume(s) £14.296 1,523.594
£14.296 2,121.579

- d) Aggregated information 4,180.105
Aggregated volume Price £14.296

- e) Date of the transaction 2018-04-12
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr L Miels
- b) Position/status President, Global Pharmaceuticals

- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.	
c) Price(s) and volume(s)	Price(s)	Volume(s)
	£14.296	3,489.352
c) Price(s) and volume(s)	£14.296	2,410.334
	£14.296	3,628.919
d) Aggregated information	9,528.606	
d) Aggregated volume Price	£14.296	
e) Date of the transaction	2018-04-12	
f) Place of the transaction	London Stock Exchange (XLON)	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr S Dingemans
b) Position/status	Chief Financial Officer
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882	
--	--	--

b) Nature of the transaction

Increase in notional interest
in Ordinary Shares following
the re-investment of
dividends paid to
shareholders on 12 April
2018 on Ordinary Shares held
in the Company's
Performance Share Plan.

Price(s)	Volume(s)
£14.296	2,489.892

c) Price(s) and volume(s)

£14.296	3,908.186
---------	-----------

£14.296	3,224.047
---------	-----------

£14.296	3,852.243
---------	-----------

d) Aggregated information

Aggregated volume Price

13,474.367

£14.296

e) Date of the transaction

2018-04-12

f) Place of the transaction

London Stock Exchange
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name

Mr N Hirons

b) Position/status

SVP, Global Ethics &
Compliance

c) Initial notification/
amendment

Initial notification

2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a) Name

GlaxoSmithKline plc

b) LEI

5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted

a) Description of the financial instrument

Ordinary shares of 25 pence
each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction

Increase in notional interest
in Ordinary Shares following
the re-investment of
dividends paid to

shareholders on 12 April
2018 on Ordinary Shares held
in the Company's
Performance Share Plan.

Price(s) Volume(s)

£14.296 876.631

c) Price(s) and volume(s) £14.296 748.274

£14.296 1,036.207

Aggregated information

d) 2,661.111

Aggregated volume Price £14.296

e) Date of the transaction 2018-04-12

f) Place of the transaction London Stock Exchange
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D S Redfern

b) Position/status Chief Strategy Officer

c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each date; and (iv) each place where
transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each
('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest in Ordinary
Shares following the re-investment of
dividends paid to shareholders on 12
April 2018 on Ordinary Shares held in
the Company's Performance Share Plan.

c) Price(s) and volume(s) Price(s) Volume(s)
£14.296 1,540.732

£14.296 1,453.809

£14.296 1,915.390

Aggregated information

d)	
Aggregated volume Price	4,909.931 £14.296
e) Date of the transaction	2018-04-12
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Ms C Thomas
b) Position/status	SVP, HR
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
--	--

b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.
------------------------------	--

	Price(s)	Volume(s)
	£14.296	1,939.201
c) Price(s) and volume(s)	£14.296	1,603.457
	£14.296	2,171.486

Aggregated information

d)	
Aggregated volume Price	5,714.144 £14.296
e) Date of the transaction	2018-04-12
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr P C Thomson
b) Position/status President, Global Affairs
Initial

c) notification/ Initial notification
amendment
Details of the issuer, emission allowance

2. market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.

	Price(s)	Volume(s)
	£14.296	1,115.711

	Price(s)	Volume(s)
c) Price(s) and volume(s)	£14.296	1,004.831
	£14.296	1,365.746

d) Aggregated information 3,486.288
Aggregated volume Price £14.296

e) Date of the transaction 2018-04-12

f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mrs V A Whyte
 - b) Position/status Company Secretary
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882								
b) Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Performance Share Plan.								
c) Price(s) and volume(s)	<table border="0"> <thead> <tr> <th style="text-align: left;">Price(s)</th> <th style="text-align: left;">Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£14.296</td> <td>212.997</td> </tr> <tr> <td>£14.296</td> <td>199.988</td> </tr> <tr> <td>£14.296</td> <td>189.843</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£14.296	212.997	£14.296	199.988	£14.296	189.843
Price(s)	Volume(s)								
£14.296	212.997								
£14.296	199.988								
£14.296	189.843								
d) Aggregated information									
Aggregated volume	602.829								
Price	£14.296								
e) Date of the transaction	2018-04-12								
f) Place of the transaction	London Stock Exchange (XLON)								

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr B McNamara
 - b) Position/status CEO, GSK Consumer Healthcare
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

a) Description of the financial instrument American Depositary Shares
 ('ADSs')
 ISIN: US37733W1053

b) Nature of the transaction Increase in notional interest
 in ADSs following the
 re-investment of dividends
 paid to shareholders on 12
 April 2018 on ADSs held in
 the Company's Performance
 Share Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	\$40.62	866.909
	\$40.62	1,399.614
	\$40.62	1,727.388

d) Aggregated information 3,993.911
 Aggregated volume Price \$40.62

e) Date of the transaction 2018-04-12
 f) Place of the transaction New York Stock Exchange
 (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr D E Troy
 b) Position/status SVP & General Counsel
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

a) Description of the financial instrument American Depositary Shares
 ('ADSs')
 ISIN: US37733W1053

b) Nature of the transaction Increase in notional interest
 in ADSs following the
 re-investment of dividends

paid to shareholders on 12
April 2018 on ADSs held in
the Company's Performance
Share Plan.

	Price(s)	Volume(s)
c) Price(s) and volume(s)	\$40.62	1,775.668
	\$40.62	1,559.572

d) Aggregated information	3,335.240
Aggregated volume Price	\$40.62

e) Date of the transaction	2018-04-12
f) Place of the transaction	New York Stock Exchange (XNYS)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr H Barron
b) Position/status	Chief Scientific Officer and President, R&D

c) Initial notification/ amendment	Initial notification
---------------------------------------	----------------------

2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted

a) Description of the financial instrument	American Depositary Shares (‘ADSs’) ISIN: US37733W1053
--	--

b) Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Performance Share Plan.
------------------------------	--

	Price(s)	Volume(s)
c) Price(s) and volume(s)	\$40.62	3,711.539

d) Aggregated information	n/a (single transaction)
---------------------------	--------------------------

d) Aggregated volume Price	
----------------------------	--

e) Date of the transaction	2018-04-12
----------------------------	------------

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- f) Place of the transaction New York Stock Exchange
(XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Ms K Terrell
- b) Position/status Chief Digital & Technology
Officer
- c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
- a) Description of the financial instrument American Depositary Shares
(‘ADSs’)
ISIN: US37733W1053
- b) Nature of the transaction Increase in notional interest
in ADSs following the
re-investment of dividends
paid to shareholders on 12
April 2018 on ADSs held in
the Company's Performance
Share Plan.
- c) Price(s) and volume(s) Price(s) Volume(s)
\$40.62 1,432.209
- d) Aggregated information n/a (single transaction)
- e) Aggregated volume Price
- e) Date of the transaction 2018-04-12
- f) Place of the transaction New York Stock Exchange
(XNYS)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: April 17, 2018

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc